These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33082372)

  • 1. Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study.
    Etzion O; Dahari H; Yardeni D; Issachar A; Nevo-Shor A; Cohen-Naftaly M; Ashur Y; Uprichard SL; Arbib OS; Munteanu D; Braun M; Cotler SJ; Abufreha N; Keren-Naus A; Shemer-Avni Y; Mor O; Murad J; Novack V; Shlomai A
    Sci Rep; 2020 Oct; 10(1):17820. PubMed ID: 33082372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
    Perpiñán E; Caro-Pérez N; García-González N; Gregori J; González P; Bartres C; Soria ME; Perales C; Lens S; Mariño Z; Londoño MC; Ariza X; Koutsoudakis G; Quer J; González-Candelas F; Forns X; Pérez-Del-Pulgar S
    J Viral Hepat; 2018 Dec; 25(12):1515-1525. PubMed ID: 30141252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
    Gupta N; Manirambona L; Shumbusho F; Kabihizi J; Murangwa A; Serumondo J; Makuza JD; Nsanzimana S; Muvunyi CM; Mukabatsinda C; Musabeyezu E; Camus G; Grant PM; Kateera F
    Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):542-551. PubMed ID: 35248212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).
    Sulkowski MS; Flamm S; Kayali Z; Lawitz EJ; Kwo P; McPhee F; Torbeyns A; Hughes EA; Swenson ES; Yin PD; Linaberry M
    Liver Int; 2017 Jun; 37(6):836-842. PubMed ID: 27943563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Jacobson IM; Lawitz E; Gane EJ; Willems BE; Ruane PJ; Nahass RG; Borgia SM; Shafran SD; Workowski KA; Pearlman B; Hyland RH; Stamm LM; Svarovskaia E; Dvory-Sobol H; Zhu Y; Subramanian GM; Brainard DM; McHutchison JG; Bräu N; Berg T; Agarwal K; Bhandari BR; Davis M; Feld JJ; Dore GJ; Stedman CAM; Thompson AJ; Asselah T; Roberts SK; Foster GR
    Gastroenterology; 2017 Jul; 153(1):113-122. PubMed ID: 28390869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
    Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S; Yousuf MH; Yousaf MI
    World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
    Wei L; Lim SG; Xie Q; Văn KN; Piratvisuth T; Huang Y; Wu S; Xu M; Tang H; Cheng J; Le Manh H; Gao Y; Mou Z; Sobhonslidsuk A; Dou X; Thongsawat S; Nan Y; Tan CK; Ning Q; Tee HP; Mao Y; Stamm LM; Lu S; Dvory-Sobol H; Mo H; Brainard DM; Yang YF; Dao L; Wang GQ; Tanwandee T; Hu P; Tangkijvanich P; Zhang L; Gao ZL; Lin F; Le TTP; Shang J; Gong G; Li J; Su M; Duan Z; Mohamed R; Hou JL; Jia J
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):127-134. PubMed ID: 30555048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
    Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
    BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
    Tao YC; Deng R; Wang ML; Lv DD; Yuan M; Wang YH; Chen EQ; Tang H
    Virol J; 2018 Oct; 15(1):150. PubMed ID: 30285800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
    Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct acting antivirals failure: cause and retreatment options.
    Parlati L; Pol S
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial.
    Kateera F; Shumbusho F; Manirambona L; Kabihizi J; Murangwa A; Serumondo J; Makuza JD; Nsanzimana S; Muvunyi CM; Kabakambira JD; Sylvain H; Camus G; Grant PM; Gupta N
    Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):533-541. PubMed ID: 35248213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
    Hezode C; Reau N; Svarovskaia ES; Doehle BP; Shanmugam R; Dvory-Sobol H; Hedskog C; McNally J; Osinusi A; Brainard DM; Miller MD; Mo H; Roberts SK; O'Leary JG; Shafran SD; Zeuzem S
    J Hepatol; 2018 May; 68(5):895-903. PubMed ID: 29221887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
    Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
    Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
    World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.